Effects of long-acting testosterone undecanoate on bone mineral density in middle-aged men with late-onset hypogonadism and metabolic syndrome: Results from a 36 months controlled study

Aging Male

Volumn 15, Issue 2, 2012, Pages 96-102

  Aversa, Antonio ^a   Bruzziches, Roberto ^a   Francomano, Davide ^a   Greco, Emanuela A ^a   Fornari, Rachele ^a   Luigi, Luigi Di ^b   Lenzi, Andrea ^a   Migliaccio, Silvia ^a,b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF ROME FORO ITALICO   (Italy)

Author keywords

Diabetes mellitus; Dual energy x ray absorptiometry; Male; Osteopenia; Testosterone replacement therapy

Indexed keywords

ESTRADIOL; LONG ACTING DRUG; TESTOSTERONE UNDECANOATE;

ABSENCE OF SIDE EFFECTS; ADULT; ANDROGEN THERAPY; ARTICLE; BONE DENSITY; BONE MASS; CONTROLLED STUDY; DISEASE MARKER; DRUG BLOOD LEVEL; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMUR; HUMAN; HYPOGONADISM; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; OSTEOPENIA; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT CONTRAINDICATION; TREATMENT DURATION; VERTEBRA;

AGED; ANDROGENS; BONE DENSITY; FEMUR; HUMANS; HYPOGONADISM; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; SPINE; TESTOSTERONE;

EID: 84860860432     PISSN: 13685538     EISSN: 14730790     Source Type: Journal    
DOI: 10.3109/13685538.2011.631230     Document Type: Article

References (50)

1. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis, prevention, diagnosis, and therapy. JAMA 2001;285:785-795.
2. Liu H, Paige NM, Goldzweig CL, Wong E, Zhou A, Suttorp MJ, Munjas B, et al. Screening for osteoporosis in men: a systematic review for an American College of Physicians guideline. Ann Intern Med 2008;148:685-701.
3. Hamilton EJ, Ghasem-Zadeh A, Gianatti E, Lim-Joon D, Bolton D, Zebaze R, Seeman E, et al. Structural decay of bone microarchitecture in men with prostate cancer treated with androgen deprivation therapy. J Clin Endocrinol Metab 2010;95:E456-E463.
4. Rucker D, Ezzat S, Diamandi A, Khosravi J, Hanley DA. IGF-and testosterone levels as predictors of bone mineral density in healthy, community-dwelling men. Clin Endocrinol (Oxf) 2004;60: 491-499.
5. Olszynski WP, Shawn Davison K, Adachi JD, Brown JP, Cummings SR, Hanley DA, Harris SP, et al. Osteoporosis in men: epidemiology, diagnosis, prevention, and treatment. Clin Ther 2004;26:15-28.
6. Amory JK, Watts NB, Easley KA, Sutton PR, Anawalt BD, Matsumoto AM, Bremner WJ, Tenover JL. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab 2004;89:503-510.
7. Meier C, Nguyen TV, Handelsman DJ, Schindler C, Kushnir MM, Rockwood AL, Meikle AW, et al. Endogenous sex hormones and incident fracture risk in older men: the Dubbo Osteoporosis Epidemiology Study. Arch Intern Med 2008;168:47-54.
8. LeBlanc ES, Nielson CM, Marshall LM, Lapidus JA, Barrett-Connor E, Ensrud KE, Hoffman AR, et al.; Osteoporotic Fractures in Men Study Group. The effects of serum testosterone, estradiol, and sex hormone binding globulin levels on fracture risk in older men. J Clin Endocrinol Metab 2009;94:3337-3346.
9. Isidori AM, Giannetta E, Greco EA, Gianfrilli D, Bonifacio V, Isidori A, Lenzi A, Fabbri A. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a metaanalysis. Clin Endocrinol (Oxf) 2005;63:280-293.
10. Tracz MJ, Sideras K, Bolona ER, Haddad RM, Kennedy CC, Uraga MV, Caples SM, et al. Testosterone use in men and its effects on bone health. A systematic review and meta-analysis of randomized placebo- controlled trials. J Clin Endocrinol Metab 2006;91:2011-2016.
11. MacLean C, Newberry S, Maglione M, McMahon M, Ranganath V, Suttorp M, Mojica W, et al. Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med 2008;148:197-213.
12. Corona G, Rastrelli G, Vignozzi L, Mannucci E, Maggi M. Testosterone, cardiovascular disease and the metabolic syndrome. Best Pract Res Clin Endocrinol Metab 2011;25:337-353.
13. Greco EA, Fornari R, Rossi F, Santiemma V, Prossomariti G, Annoscia C, Aversa A, et al. Is obesity protective for osteoporosis? Evaluation of bone mineral density in individuals with high body mass index. Int J Clin Pract 2010;64:817-820.
14. Corona G, Monami M, Rastrelli G, Aversa A, Tishova Y, Saad F, Lenzi A, et al. Testosterone and metabolic syndrome: a meta-analysis study. J Sex Med 2011;8:272-283.
15. Corona G, Rastrelli G, Morelli A, Vignozzi L, Mannucci E, Maggi M. Hypogonadism and metabolic syndrome. J Endocrinol Invest 2011;34:557-567.
16. Aversa A, Bruzziches R, Francomano D, Rosano G, Isidori AM, Lenzi A, Spera G. Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 24-month, randomized, double-blind, placebo-controlled study. J Sex Med 2010;7:3495-3503.
17. Edelstein SL, Barrett-Connor E. Relation between body size and bone mineral density in elderly men and women. Am J Epidemiol 1993;138:160-169.
18. Hannan MT, Felson DT, Anderson JJ. Bone mineral density in elderly men and women: results from the Framingham osteoporosis study. J Bone Miner Res 1992;7:547-553.
19. Nguyen TV, Sambrook PN, Eisman JA. Bone loss, physical activity, and weight change in elderly women: the Dubbo Osteoporosis Epidemiology Study. J Bone Miner Res 1998;13:1458-1467.
20. Reid IR, Evans MC, Cooper GJ, Ames RW, Stapleton J. Circulating insulin levels are related to bone density in normal postmenopausal women. Am J Physiol 1993;265:E655-E659.
21. Premaor MO, Pilbrow L, Tonkin C, Parker RA, Compston J. Obesity and fractures in postmenopausal women. J Bone Miner Res 2010;25:292-297.
22. Alberti KG, Zimmet P, Shaw J; IDF Epidemiology Task Force Consensus Group. The metabolic syndrome - a new worldwide definition. Lancet 2005;366:1059-1062.
23. Morales A, Lunenfeld B; International Society for the Study of the Aging Male. Investigation, treatment and monitoring of lateonset hypogonadism in males. Official recommendations of ISSAM. International Society for the Study of the Aging Male. Aging Male 2002;5:74-86.
24. Moore C, Huebler D, Zimmermann T, Heinemann LA, Saad F, Thai DM. The Aging Males' Symptoms scale (AMS) as outcome measure for treatment of androgen deficiency. Eur Urol 2004;46:80-87.
25. Prior BM, Cureton KJ, Modlesky CM, Evans EM, Sloniger MA, Saunders M, Lewis RD. In vivo validation of whole body composition estimates from dual-energy X-ray absorptiometry. J Appl Physiol 1997;83:623-630.
26. Gluer CC. Monitoring skeletal changes by radiological techniques. J Bone Miner Res 1999;14:1952-1962.
27. Aversa A, Bruzziches R, Francomano D, Spera G, Lenzi A. Efficacy and safety of two different testosterone undecanoate formulations in hypogonadal men with metabolic syndrome. J Endocrinol Invest 2010;33:776-783.
28. Heidenreich A, Aus G, Abbou CC. Guidelines on prostate cancer. European Association of Urology, ed. 2010. Available at: www.uroweb. org/gls/pdf/ Prostate%20Cancer%202010.pdf
29. Wiren KM, Toombs AR, Semirale AA, Zhang X. Osteoblast and osteocyte apoptosis associated with androgen action in bone: requirement of increased Bax/Bcl-2 ratio. Bone 2006;38:637-651.
30. Notini AJ, McManus JF, Moore A, Bouxsein M, Jimenez M, Chiu WS, Glatt V, et al. Osteoblast deletion of exon 3 of the androgen receptor gene results in trabecular bone loss in adult male mice. J Bone Miner Res 2007;22:347-356.
31. Pacifici R. The immune system and bone. Arch Biochem Biophys 2010;503:41-53.
32. Corona G, Monami M, Boddi V, Cameron-Smith M, Fisher AD, de Vita G, Melani C, et al. Low testosterone is associated with an increased risk of MACE lethality in subjects with erectile dysfunction. J Sex Med 2010;7:1557-1564.
33. Kinjo M, Setoguchi S, Solomon DH. Bone mineral density in adults with the metabolic syndrome: analysis in a population-based U.S. sample. J Clin Endocrinol Metab 2007;92:4161-4164.
34. Ahmed LA, Schirmer H, Berntsen GK, Fonnebo V, Joakimsen RM. Features of the metabolic syndrome and the risk of non-vertebral fractures: the Tromso study. Osteoporos Int 2006;17:426-432.
35. von Muhlen D, Safii S, Jassal SK, Svartberg J, Barrett-Connor E. Associations between the metabolic syndrome and bone health in older men and women: the Rancho Bernardo Study. Osteoporos Int 2007;18:1337-1344.
36. Hwang DK, Choi HJ. The relationship between low bone mass and metabolic syndrome in Korean women. Osteoporos Int 2010;21: 425-431.
37. Kim HY, Choe JW, Kim HK, Bae SJ, Kim BJ, Lee SH, Koh JM, et al. Negative association between metabolic syndrome and bone mineral density in Koreans, especially in men. Calcif Tissue Int 2010;86:350-358.
38. Hernandez JL, Olmos JM, Pariente E, Martinez J, Valero C, Garcia- Velasco P, Nan D, et al. Metabolic syndrome and bone metabolism: the Camargo Cohort study. Menopause 2010;17:955-961.
39. Vignozzi L, Morelli A, Filippi S, Maggi M, Forti G. Male pubertal development: role of androgen therapy on bone mass and body composition. J Endocrinol Invest 2010;33:27-32.
40. Lorentzon M, Swanson C, Andersson N, Mellstrom D, Ohlsson C. Free testosterone is a positive, whereas free estradiol is a negative, predictor of cortical bone size in young Swedish men: the GOOD study. J Bone Miner Res 2005;20:1334-1341.
41. Jackson JA, Riggs MW, Spiekerman AM. Testosterone deficiency as a risk factor for hip fractures in men: a case-control study. Am J Med Sci 1992;304:4-8.
42. Khosla S, Melton LJ 3rd, Atkinson EJ, O'Fallon WM. Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men. J Clin Endocrinol Metab 2001;86:3555-3561.
43. Carani C, Qin K, Simoni M, Faustini-Fustini M, Serpente S, Boyd J, Korach KS, Simpson ER. Effect of testosterone and estradiol in a man with aromatase deficiency. N Engl J Med 1997;337:91-95.
44. Korach KS, Couse JF, Curtis SW, Washburn TF, Lindzey J, Kimbro KS, Eddy EM, et al. Estrogen receptor gene disruption: molecular characterization and experimental and clinical phenotypes. Recent Prog Horm Res 1996;51:159-86; discussion 186.
45. McDougall KE, Perry MJ, Gibson RL, Colley SM, Korach KS, Tobias JH. Estrogen receptor-alpha dependency of estrogen's stimulatory action on cancellous bone formation in male mice. Endocrinology 2003;144:1994-1999.
46. Minnemann T, Schubert M, Hubler D, Gouni-Berthold I, Freude S, Schumann C, Oettel M, et al. A four-year efficacy and safety study of the long-acting parenteral testosterone undecanoate. Aging Male 2007;10:155-158.
47. Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, Holmes JH, Dlewati A, et al. Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab 1999;84:1966-1972.
48. Wang C, Cunningham G, Dobs A, Iranmanesh A, Matsumoto AM, Snyder PJ, Weber T, et al. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab 2004;89:2085-2098.
49. Svartberg J, Agledahl I, Figenschau Y, Sildnes T, Waterloo K, Jorde R. Testosterone treatment in elderly men with subnormal testosterone levels improves body composition and BMD in the hip. Int J Impot Res 2008;20:378-387.
50. Saad F, Aversa A, Isidori AM, Zafalon L, Zitzmann M, Gooren L. Onset of effects of testosterone treatment and time span until maximum effects are achieved. Eur J Endocrinol 2011;165: 675-685.